What Jazz’s Ziihera approval means for trastuzumab — and for PD-1 — in first-line HER2+ gastroesophageal cancer
FDA cleared two zanidatamab regimens on 25 August, including a bispecific-plus-PD-1 combination for all HER2+ advanced GEA regardless of PD-L1 status, on Phase 3 data already in NEJM.
